Structure-activity relationships among 2-substituted 5,6-dichloro-, 4,6-dichloro-, and 4,5-dichloro-1-[(2-hydroxyethoxy)methyl]- and -1-[(1,3-dihydroxy-2-propoxy)methyl]benzimidazoles

Journal of Medicinal Chemistry

Volumn 39, Issue 4, 1996, Pages 881-891

  Saluja, Sunita ^a   Zou, Ruiming ^b   Drach, John C ^c   Townsend, Leroy B ^c  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b GILEAD SCIENCES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DICHLORO 1 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]BENZIMIDAZOLE DERIVATIVE; 4,5 DICHLORO 1 [(2 HYDROXYETHOXY)METHYL]BENZIMIDAZOLE DERIVATIVE; 4,6 DICHLORO 1 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]BENZIMIDAZOLE DERIVATIVE; 4,6 DICHLORO 1 [(2 HYDROXYETHOXY)METHYL]BENZIMIDAZOLE DERIVATIVE; 5,6 DICHLORO 1 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]BENZIMIDAZOLE DERIVATIVE; 5,6 DICHLORO 1 [(2 HYDROXYETHOXY)METHYL]BENZIMIDAZOLE DERIVATIVE; AMMONIA; BENZIMIDAZOLE DERIVATIVE; BENZYL CHLORIDE; DIMETHYLAMINE; METHYLAMINE; NUCLEOSIDE DERIVATIVE; POTASSIUM CYANIDE; SODIUM CARBONATE; THIOUREA; UNCLASSIFIED DRUG;

ALKYLATION; ANTIVIRAL ACTIVITY; ARTICLE; DEACETYLATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HERPESVIRUS 1, HUMAN; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030067363     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950556a     Document Type: Article

References (58)

1. MacCoss, M.; Tolman, R. L.; Ashton, W. T.; Wagner, A. F.; Hannah, J.; Field, A. K.; Karkas, J. D.; Germershausen, J. I. Synthetic, Biochemical and Antiviral Aspects of Selected Acyclonucleosides and Their Derivatives. Chem. Scr. 1986, 26, 113-121.
2. Schaeffer, H. J.; Beauchamp, L.; De Miranda, P.; Elion, G. B.; Bauer, D. J.; Collins, P. 9-(2-Hydroxyethoxymethyl)guanine Activity Against Viruses of the Herpes Group. Nature 1978, 272, 583-589.
3. Field, A. K.; Davies, M. E.; Dewitt, C.; Perry, H. C.; Liou, R.; Germershausen, J.; Karkas, J. D.; Ashton, W. T.; Johnston, D. B.; Tolman, R. L. 9-([2-Hydroxy-1-hydroxymethyl)ethoxy]-methyl)-guanine: A Selective Inhibitor of Herpes Group Virus Replication. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4139-4143.
4. Drach, J. P. Purine Nucleosides as an Antiviral Agents. In Targets for the Design of Antiviral Agents; De Clercq, E., Walker, R. T., Eds.; Plenum Press: New York, 1984; pp 231-257.
5. De Clereq, E.; Descamps, J.; De Somer, P.; Barr, P. J.; Jones, A. S.; Walker, R. T. (E)-5-(2-Bromovinyl)-2′-deoxyuridines: A Potent and Selective Antiherpes Agent. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2947-2951.
6. Watanabe, K. A.; Reichman, V.; Hirota, K.; Lopez, C.; Fox, J. J. Nucleosides. 110. Synthesis and Antiherpes Virus Activity of Some 2′-Fluoro-2′-deoxyarabinofuranosylpyrimidine Nucleosides. J. Med. Chem. 1979, 22, 21-24.
7. Faulds, D.; Heel, R. C. Ganciclovir. A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cytomegalovirus Infections. Drugs 1990, 39, 597-638.
8. Chrisp, P.; Clissold, S. P. Foscarnet. A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic use in Immunocompromised Patients with Cytomegalovirus Retinitis. Drugs 1991, 41, 104-129.
9. Gozlan, J.; Salford, J. M.; Roullet, E.; Baudrimont, M.; Caburet, F.; Picard, O.; Meyohas, M. C.; Duvivier, C.; Jacomet, C.; Petit, J. C. Rapid Detection of Cytomegalovirus DNA in Cerebrospinal Fluid of AIDS Patients with Neurologic Disorders. J. Infect. Dis. 1992, 166, 1416-1421.
10. (a) Germershausen, J.; Bostedor, R.; Field, A. K.; Perry, H.; Liou, R.; Bull, H.; Tolman, R. L.; Karkas, J. D. A Comparison of the Antiviral agents 2′-nor-2′-deoxyguanosine And Acyclovir: Uptake and Phosphorylation in Tissue Culture and Kinetics of in vitro inhibition of Viral and Cellular DNA Polymerase by their respective Triphosphates. Biochem. Biophys. Res. Commun. 1983, 116, 360-367.
11. (b) Biron, K. K.; Stanat, S. C.; Sorrell, J. B.; Fyfe, J. A.; Keller, P. M.; Lambe, C. U.; Nelson, D. J. Metabolic Activation of the Nucleoside Analog 9-[(2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in Human Diploid Fibroblasts Infected with Human Cytomegalovirus. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2473-2477.
12. Crumpacker, C. S.; Schnipper, L. E.; Zaia, J. A.; Levin, M. J. Growth Inhibition by Acycloguanosine of Herpesviruses Isolated from Human Infections. Antimicrob. Agents Chemother. 1979, 15, 642-645.
13. Sullivan, V. C.; Talarico, C. L.; Stanat, S. C.; Davis, M.; Coen, D. M.; Biron, K. K. A. Protein Kinase Homolog Controls Phosphorylation of Ganciclovir in Human Cytomegalovirus-Infected Cells. Nature (London) 1992, 358, 162-164.
14. Biron, K. K.; Fyfe, J. A.; Stanat, S. C.; Leslie, L. K.; Sorrell, J. B.; Lambe, C. U.; Coen, D. M. A Human Cytomegalovirus Mutant Resistant to the Nucleoside Analog 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy}methyl)guanine (BW B759u) Induces Reduced Levels of BW B759 Triphosphates. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 8769-8773.
15. Field, A. K.; Biron, K. K. "The End of Innocene" Revisited: Resistance of Herpesviruses to Antiviral Drugs. Clin. Microbiol. Rev. 1994, 7, 1-13.
16. (153 (a) Reardon, J. E.; Spector, T. Herpes simplex virus type 1 DNA polymerase. Mechanism of Inhibition by Acyclovir Triphosphate. J. Biol. Chem. 1989, 264, 7405-7411.
17. (b) Reardon, J. E. Herpes Simplex Virus Type 1 and Human DNA Polymerase Interactions with 2′-Deoxyguanosine-5′-Triphosphate Analogues. J. Biol. Chem. 1989, 264, 19039-19044.
18. Datema, R.; Ericson, A. C.; Field, H. J.; Larson, A.; Stenberg, K. Critical Determinants of Antiherpes Efficacy of Buciclovir and Related Acyclic Guanosine Analogs. Antiviral Res. 1987, 7, 303-316.
19. Chu, C. K.; Cutler, S. J. Chemistry and Antiviral Activities of Acyclonucleosides. J. Heterocycl. Chem. 1986, 23, 289-319.
20. Tamm, I.; Folkers, K.; Shunk, C. H.; Horsfall, F. L. Inhibition of Influenza Virus Multiplication by N-Glycosides of Benzimidazoles. J. Exp. Med. 1954, 99, 227-250.
21. Tamm, I.; Sehgal, P. B. Halobenzimidazole Ribosides and RNA Synthesis of Cells and Viruses. Adv. Virus Res. 1978, 22, 187-258.
22. (a) Tamm, I.; Overman, J. R. Relationship Between Structure and Benzimidazole Derivatives and Inhibitory Activity on Vaccinia Virus Multiplication. Virology 1957, 3, 185-196.
23. (b) Pothier, P.; Dru, A.; Beaud, G. The Inhibition of Vaccinia Virus Replication by 5,6-Dichloro-1-β-D-Ribofuranosylbenzimidazole (DRB): an Effect at the Assembly Stage. J. Gen. Virol. 1981, 55, 87-94.
24. (a) Tamm, I. Ribonucleic Acid Synthesis and Influenza Virus Multiplication. Science 1957, 126, 1235-1236.
25. (b) Tamm, I.; Nemes, M. M.; Osterhout, S. On the Role of Ribonucleic Acid in Animal Virus Synthesis. I. Studies with 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole. J. Exp. Med. 1960, 111, 339-349.
26. (c) Sehgal, P. B.; Fraser, N. W.; Darnell, J. E. Early Ad-2 Transcription Units: Only Promoter-Proximal RNA Continues to be Made in the presence of DRB. Virology 1979, 94, 185-191.
27. (d) Fraser, N. W.; Sehgal, P. B.; Darnell, J. E. Multiple Discrete Sites for Premature RNA-Chain Termination Late in Adenovirus-2 Infection: Enhancement by 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2571-2575.
28. (a) Harlow, P.; Molloy, G. Effect of 5,6-dichloro-1-β-D-ribofuranoyslbenzimidazole on Ribonucleotide Metabolism and Accumulation of Mitochondrial Rna and Low-Molecular-Weight Cytoplasmic Rna in Hela Cells. Arch. Biochem. Biophys. 1980, 203, 764-773.
29. (b) Tamm, I.; Kikuchi, J. E.; Salditt-Georgieff, M. Short Capped hnRNA Precursor Chains in Hela Cells: Continued Synthesis in the Presence of 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole. Biochemistry 1980, 19, 2743-2748.
30. Chodosh, L. A.; Fire, A; Samuels, M.; Sharp, P. A. 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole Inhibits Transcription Elongation by RNA Polymerase II in vitro. J. Biol. Chem. 1989, 264, 2250-2257.
31. Bucknall, R. A. The Effects of Substituted Benzimidazoles on the Growth of Viruses and the Nucleic Acid Metabolism of Host Cells. J. Gen. Virol. 1967, 1, 89-99.
32. Townsend, L. B.; Revankar, G. R. Benzimidazole Nucleosides, Nucleotides, And Related Derivatives. Chem. Rev. 1970, 70, 389-438.
33. (a) Smith, C. M.; Zombor, G.; Henderson, J. F. Inhibitors of Hypoxanthine Metabolism in Ehrlich Ascites Tumor Cells in vitro. Cancer Treat. Rep. 1976, 60, 1567-1583.
34. (b) Drug Research and Development Chemotherapy, National Cancer Institute, report of March 1, 1972, to L. B. Townsend.
35. (a) Townsend, L. B.; Devivar, R. V.; Turk, S. R.; Nassiri, M. R.; Drach, J. C. Design, Synthesis and Antiviral Activity of Certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 1995, 38, 4098-4105.
36. (b) Townsend, L. B. Benzimidazole Ribonucleosides: Design, Synthesis, and Evaluation of 2,5,6-Trichloro-1-(β-D-ribofuranosyl) benzimidazole (TCRB), 2-Bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole (BDCRB), and Some Structurally Related Analogs as Agents for Human Cytomegalovirus Infections. Fifth International Conference on Antiviral Research, Vancouver, BC, Canada, March 8-13, 1992.
37. (c) Drach, J. C.; Townsend, L. B.; Nassiri, M. R.; Turk, S. R.; Coleman, L. A.; Devivar, R. V.; Genzlinger, G.; Kreske, E. D.; Renau, T. E.; Westerman, A. C.; Shipman, C., Jr.; Biron, K. K.; Dornsife, R.; Kern, E. R. Benzimidazole Ribonucleosides: A New Class of Antivirals with Potent and Selective Activity Against Human Cytomegalovirus. Fifth International Conference on Antiviral Research, Vancouver, BC, Canada, March 8-13, 1992.
38. (a) Underwood, M. R.; Biron, K. K.; Hemphill, M. L.; Miller, T. L.; Stanat, S. C.; Dornsife, R. E.; Drach, J. C.; Townsend, L. B.; Edwards, C. A.; Harvey, R. J. High Molecular Weight HCMV DNA Does Not Properly Mature in the Presence of 2-Bromo-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (BDCRB). Herpesvirus Workshop, Pittsburgh, PA, July 1993.
39. (b) Underwood, M. R.; Stanat, S. C.; Drach, J. C.; Harvey, R. J.; Biron, K. K. Inhibition of HCMV DNA Processing by a New Class of Anti-HCMV Compounds is Mediated Through the UL89 Gene Product. Herpesvirus Workshop, Vancouver, BC, August 1994.
40. Mandel, L. R.; Porter, C. C., Jr.; Kuehl, F. A.; Jensen, N. P.; Schmitt, S. M.; Windholz, T.; Beattie, T. R.; Carty, J. A.; Christensen, B. G.; Shen, T. Y. Inhibitions of Adrenal Phenethanolamine N-Methyltransferase by Substituted Benzimidazoles. J. Med. Chem. 1970, 13, 1043-1047.
41. Kazimierczuk, Z.; Cottam, H. B.; Revankar, G. R.; Robins, R. K. Synthesis of 2′-Deoxy tubercidin, 2′-Deoxyadenosine, and Related 2′-Deoxynucleosides via a Novel Direct Stereospecific Sodium Salt Glycosylation Procedure. J. Am. Chem. Soc. 1984, 106, 6379-6382.
42. Kawashima, E.; Gupta, P. K.; Devivar, R. V.; Townsend, L. B. 2,5,6-Trichlorobenzimidazole. In Nucleic Acid Chemistry; Townsend, L. B., Tipson, R. S., Eds.; John Wiley and Sons: New York, 1991; Part 4, pp 24-26.
43. Zou, R.; Townsend, L. B. Unpublished results.
44. (a) Chloromethylation of 2-(benzyloxy)ethanol (Aldrich) with p-formaldehyde and HCl (gas) gave 2-(benzyloxy)-1-(chloromethoxy)ethane.
45. (b) Butler, C. L.; Renfrew, A. G.; Clapps, M. The Preparation of Benzyloxyalkyl p-toluenesulfonates. J. Am. Chem. Soc. 1938, 60, 1472-1473.
46. Martin, J. C.; Dvorak, C. A.; Smee, D. F.; Matthews, T. R.; Verheyden, J. P. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: A New Potent and Selective Antiherpes Agent. J. Med. Chem. 1983, 26, 759-761.
47. Oglivie, K. K.; Nguyen, BA.N.; Hamilton, R. G. A Trihydroxy Acyclonucleoside Series. Can. J. Chem. 1984, 62, 1622-1627.
48. Rosemeyer, H.; Toth, G.; Seela, F. Assignment of Anomeric Configuration of D-Ribo-Arabino-2′-Deoxyribo-, and 2′,3′-Dideoxyribonucleosides by NOE Difference Spectroscopy. Nucleosides Nucleotides 1989, 8, 587-597.
49. Harrison, D.; Ralph, J. T. Nucleophilic Substitution Reaction of 2-Chlorobenzimidazoles. Part I. Formation of Benzimidazolin-2-ones and 2-Alkoxybenzimidazoles. J. Chem. Soc. 1965, 236-239.
50. Silverstein, R. M.; Bassler, G. C. Infrared Spectrometry "Spectrometric Identification of Organic Compounds" 2nd ed.; John Wiley and Sons, Inc.: New York, 1976; pp 95-105.
51. Robins, M. J.; Hatfield, P. W. Nucleic Acid Related Compounds. 37. Convenient and High-yield Syntheses of N-[(2-Hydroxyethoxy)methyl]heterocycles as "Acyclic Nucleoside" Analogues. Can. J. Chem. 1982, 60, 547-533.
52. Beauchamp, L. M.; Serling, B. L.; Kelsey, J. E.; Biron, K. K.; Collins, P.; Selway, J.; Lin, J. C.; Schaeffer, H. J. Effect of Acyclic Pyrimidines Related to 9-[(1,3-Dihydroxy-2-propoxy]methyl]-guanine on Herpesviruses. J. Med. Chem. 1988, 31, 144-149.
53. Devivar, R. V.; Kawashima, E.; Revankar, G. R.; Breitenbach, J. M.; Drach, J. C.; Townsend, L. B. Benzimidazole Ribonucleosides: Design, Synthesis and Antiviral Evaluation of Certain 2-Alkylthio-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 1994, 37, 2942-2949.
54. The solvent system in parentheses next to the melting point is solvent of crystallization and/or recrystallization.
55. Turk, S. R.; Shipman, C., Jr.; Nassiri, M. R.; Genzingler, G.; Krawczyk, S. H.; Townsend, L. B.; Drach, J. C. Pyrrolo[2,3-d]-pyrimidine Nucleosides as Inhibitors of Human Cytomegalovirus. Antimicrob. Agents Chemother. 1987, 31, 544-550.
56. Prichard, M. N.; Turk, S. R.; Coleman, L. A.; Engelhardt, S. L.; Shipman, C., Jr.; Drach, J. C. A. Microtiter Virus Yield Reduction Assay for The Evaluation of Antiviral Compounds Against Human Cytomegalovirus and Herpes Simplex Virus. J. Virol. Methods 1990, 28, 101-106.
57. Prichard, M. N.; Shipman, C., Jr. A. Three-Dimensional Model To Analyze Drug-Drug Interactions. Antiviral Res. 1990, 14, 181-206.
58. Prichard, M. N.; Prichard, L. E.; Baguley, W. A.; Nassiri, M. R.; Shipman, C., Jr. Three-Dimensional Analysis of the Synergistic Cytotoxicity of Ganciclovir and Zidovudine. Antimicrob. Agents Chemother. 1991, 35, 1060-1065.